NASDAQ · ABCL
AbCellera Biologics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ABCL: Nov 09, 2026
AbCellera Biologics Inc. Common Shares is expected to report earnings on 11/09/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.18. The reported EPS for the same quarter last year was $-0.19.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.18 | $-0.17 | $-0.20 | 3 |
| Dec 2026 | $-0.19 | $-0.19 | $-0.20 | 3 |
| Mar 2027 | $-0.20 | $-0.20 | $-0.21 | 2 |
| Jun 2027 | $-0.21 | $-0.21 | $-0.21 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · BNK Invest · The Motley Fool- Zacks · Oct 12, 4:25 PM EDTNurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesNurix Therapeutics (NRIX) delivered earnings and revenue surprises of +944.64% and +383.11%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Sep 30, 6:14 AM EDTBiotech Stocks At 52-Week Highs – IOVA +31%, XERS, GRAL, ABCL, SGHT(RTTNews) – The following biotech stocks reached a 52-week high on September 29, 2026, driven by key catalysts such as promising results from clinical trials or revised financial guidance.
- Zacks · Sep 22, 10:17 AM EDTABCL Stock Surges 121% in 3 Months: Here's What You Need to KnowAbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
- RTTNews · Sep 18, 4:36 AM EDTBiotech Stocks At 52-Week Highs – MNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO(RTTNews) – The following biotech stocks reached a 52-week high on September 17, 2026, driven by the gain on certain clinical or financial results.
- RTTNews · Aug 25, 12:11 PM EDTAbCellera Reports Q2 2026 Results, Advances ABCL635 And T-Cell Engager Pipeline(RTTNews) – AbCellera Biologics Inc. (ABCL), a clinical-stage biotechnology company developing antibody-based medicines, recently reported second-quarter 2026 financial results and provided updates across its clinical pipeline and strategic collaborations.
- BNK Invest · Aug 17, 1:52 PM EDTMonday 8/17 Insider Buying Report: ABCL, BPRNAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. At AbCellera Biologics, a filing with the SEC revealed that on Wednesday, Director
- The Motley Fool · Aug 12, 8:31 PM EDTAbCellera (ABCL) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 12, 10:03 AM EDTAbCellera Unveils $200 Mln Offering Of Shares And Pre-Funded Warrants; Stock Down(RTTNews) – AbCellera Biologics Inc. (ABCL), a clinical-stage company, announced that it has commenced an underwritten public offering of $200 million of its common shares and pre-funded warrants to purchase its common shares.
- Zacks · Aug 11, 5:55 AM EDTCompany News for Aug 11, 2026Companies In The Article Are:BA,INTC,HZO,ABCL and ACHR
- RTTNews · Aug 11, 4:05 AM EDTBiotech Stocks At 52-Week Highs – SLN +29% & ABCL +34% On Positive Trial Data, CPIX, CLDX, BDSX(RTTNews) – The following biotech stocks reached a 52-week high on August 10, 2026, driven by key catalysts such as positive quarterly reports or the release of promising results from clinical trials.
- MarketBeat · Aug 10, 9:03 AM EDTAbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II TrialArgenx's 28% Surge & Promising Product Propel Investor ConfidenceAbCellera Biologics (NASDAQ:ABCL) reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associate
- RTTNews · Aug 10, 8:53 AM EDTAbCellera's ABCL635 Delivers Strong Phase 2 Data; Stock Jumps 33%(RTTNews) – AbCellera Biologics Inc. (ABCL) announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational NK3R antagonist antibody for moderate-to-severe vasomotor symptoms due to menopause.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for AbCellera Biologics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.